News
EW
89.20
-1.20%
-1.08
Edwards Lifesciences Is Maintained at Outperform by RBC Capital
Dow Jones · 18h ago
Edwards Lifesciences Price Target Raised to $101.00/Share From $95.00 by RBC Capital
Dow Jones · 18h ago
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $101
Benzinga · 18h ago
What's in Store for Thermo Fisher (TMO) in Q1 Earnings?
NASDAQ · 20h ago
Validea Detailed Fundamental Analysis - EW
NASDAQ · 23h ago
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Edwards Lifesciences Corporation's (NYSE:EW) estimated fair value is US$76.07 based on 2 Stage Free Cash Flow to Equity. Current share price of US$90.28 suggests EW is potentially trading close to its fair value. We will use a discounted cash flow model to estimate the company's intrinsic value. The company is estimated to be worth around US$93.52 based on the current share price.
Simply Wall St · 1d ago
Weekly Report: what happened at EW last week (0408-0412)?
Weekly Report · 1d ago
EDWARDS LIFESCIENCES CORP <EW.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $105 FROM $97
Reuters · 1d ago
EDWARDS LIFESCIENCES CORP <EW.N>: RBC RAISES TARGET PRICE TO $101 FROM $95
Reuters · 1d ago
Wedgewood Partners Q1 2024 Client Letter
The year 2024 is off to a near-historic start with the S&P 500 Index gaining +10.5%. Top performance contributors for the first quarter include Meta Platforms, Tractor Supply, Edwards Lifesciences and Copart. The stock market has gained a stellar +29.9% in the past 12 months.
Seeking Alpha · 2d ago
$1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today
Benzinga · 3d ago
Can High Medical Costs Affect UnitedHealth's (UNH) Q1 Earnings?
NASDAQ · 3d ago
How Is The Market Feeling About Edwards Lifesciences?
Edwards Lifesciences's short percent of float has risen 24.11% since its last report. The company has 10.45 million shares sold short, which is 1.75% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 3d ago
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
NASDAQ · 3d ago
What Analysts Are Saying About Edwards Lifesciences Stock
10 analysts have evaluated Edwards Lifesciences (NYSE:EW) in the last three months. The 12-month price targets, analyzed by analysts, offer insights with an average target of $96.0. The company achieved a solid revenue growth rate of 13.78% in the past 3 months. Edwards Lifsciences's financial performance is impressive.
Benzinga · 4d ago
Top quant-rated consumer staples during Q1
Consumer Staples Select Sector SPDR Fund ETF (XLP) gained 4.8% in Q1. The consumer staples sector has been the worst-performing sector in the S&P 500 over the last year. The sector is considered less susceptible to economic cycles than the broader market.
Seeking Alpha · 4d ago
Noteworthy ETF Outflows: IHI, SYK, MDT, EW
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), Edwards Lifesciences (EW) and Nurix Therapeutics (NRIX)
TipRanks · 5d ago
Edwards Lifesciences Price Target Raised to $105.00/Share From $95.00 by Mizuho
Dow Jones · 5d ago
Edwards Lifesciences Is Maintained at Buy by Mizuho
Dow Jones · 5d ago
More
Webull provides a variety of real-time EW stock news. You can receive the latest news about Edwards Lifesciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EW
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.